Urinary Ιncontinence (UI)

It is the inability to control the blader and subsequent unwanted urine loss. It is a very common problem. The severity of incontinence, ranges from occasionally leaking urine when someone coughs or sneezes (Stress incontinence) to experiencing a strong urge to urinate that leads to not being able to reach WC before it’s too late (Urge incontinence). There is also a mixed type of incontinence which shares symptoms with both above types.
It is more common as people get older, but incontinence is not a direct consequence of aging. In general, incontinence is not considered to be a disease, but a symptom and can be managed with the help of your HCP.

In women, moderate and severe bother have a prevalence ranging from about 3% to 17%. Severe incontinence has a low prevalence in young women, but rapidly increases at ages 70 through 80. In men, the prevalence of incontinence is much lower than in women, about 3% to 11% overall, with urge incontinence accounting for 40% to 80% of all male patients. Stress incontinence accounts for less than 10% of cases and is attributable to prostate surgery, trauma, or neurological injury. Incontinence in men also increases with age, but severe incontinence in 70- to 80-year-old men is about half of that in women.

bibliography: Rev Urol. 2001; 3(Suppl 1): S2–S6. PMCID: PMC1476070 PMID: 16985992

Flower Pollen Extract Graminex

Pelvax r logo

“…All the groups demonstrated improvement in ICIQ-SF scores at week 24 (p < 0.001). The RCT Fem™ (Pollen extract) UI group had the greatest improvement in ICIQ-SF scores (−4.07 ± 3.4), followed by the PollenBerry® (pollen extract) group (−3.34 ± 2.87)…"

Conclusions
Pollen extract (RCT Fem™) supplementation resulted in significant and clinically meaningful reductions in UI severity, with corresponding improvements in daily urinary leakage volume and frequency of nocturia. Pollen extract (PollenBerry®) significantly improved stress-induced urinary leakage volume, suggesting that it may be efficacious in women who are prone to stress UI. The study products were safe and well tolerated in this population.”
Bibliography: Current Urology 18(3):p 203-211, September 2024. | DOI: 10.1097/CU9.0000000000000248

“…A review of placebo-controlled trials, active-controlled and open-label studies indicate that Cernitin (Graminex Pollen extract content) is a safe and effective therapy for the management of mild to moderate LUTS. By reducing bothersome symptoms, Cernitin improves quality of life. The placebocontrolled, double-blind studies with Cernitin alone and combined with other natural products especially provide evidence that Cernitin is effective in reducing nocturia, daytime frequency, and sensation of residual urine…. Concerning the use of Cernitin alone, we report on 15 open label studies and 4 double-blind, placebocontrolled studies that showed consistent reduction in subjective symptoms and overall effectiveness ratings of 75% and greater…”
bibliography: Research Communications in Pharmacology and Toxicology 8(1) 8(1), January 2003. A Critical Review of Cernitin™ for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men, National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, University of Mississippi, University, Ms. 38677 January 12, 2003. A Critical Review of Graminex Flower pollen extract for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men

“…Preoperatively there was no significative difference in IPSS, BS and VAS. IPSS Group A was postoperatively 7.13 (SD 1.64) and Group B was 7.33 (SD 1.58) (p=0.67); BS Group A was postoperatively 1.33 (SD 0.81), Group B was 1.73 (SD 1.09) (p=0.30), and VAS Group A was 2.73 (SD 1.9) and Group B was 4.33 (SD 1.58) (p=0.004) showing a statistically significative difference between the two groups in pelvic discomfort with a better outcome in patients treated with Graminex Pollen Extract (Cernilen-flogo®). CONCLUSIONS: Our study showed that Cernilen-flogo® treatment after PVP is effective and minimize patient’s pelvic discomfort showed by lower VAS level resulting in better postoperatively patient’s quality of life (QOL)…”
Bibliography: European Review for Medical and Pharmacological Sciences 2020; 24: 9116-9120. Postoperative treatment with phytotheraphy Graminex G63 (CERNILEN-Flogo®) after greenlight laser XPS (180W) photovaporization of the prostate (PVP), can affect patient’s quality of life?

** All data above are published as clinical trials and do not refer to EFSA claims. This means that they do not intend to be medical or therapeutical advice.